Musculoskeletal

Rheumatoid arthritis: early diagnosis and DMARD initiation

Clinical Overview and When to Suspect Rheumatoid Arthritis

— Prevalence ~0.5–1% of US adults; female:male ≈ 3:1; peak onset age 30–60 but can occur at any age.

— Pathogenesis: citrullination of self-proteins → anti-citrullinated protein antibodies (ACPA) → synovial T/B-cell activation, TNF/IL-6 cytokine cascade, pannus formation, bone/cartilage erosion.

— Insidious onset of symmetric polyarthritis involving small joints of hands (MCPs, PIPs) and feet (MTPs), wrists.

— Morning stiffness >1 hour improving with activity (vs <30 minutes in osteoarthritis).

— Soft, "boggy" joint swelling rather than bony hypertrophy.

— Constitutional symptoms: fatigue, low-grade fever, weight loss.

— Symptoms persisting >6 weeks (differentiates from viral/reactive arthritis which typically self-resolves).

Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory polyarthritis driven by autoimmune synovitis that, untreated, produces erosive joint destruction, disability, and excess cardiovascular mortality.

When to suspect RA in clinic:

Window of opportunity: the first 12 weeks after symptom onset is the critical period — DMARD initiation here produces the largest gains in remission and prevents irreversible erosions.

Step 3 management: When a primary care visit reveals symmetric small-joint swelling >6 weeks with elevated CRP, refer to rheumatology within weeks, not months, and start the workup (RF, anti-CCP, CRP/ESR, hand/foot films) concurrently — do not wait for the consult to begin labs.

Board pearl: RA spares the DIP joints and lumbar spine; involvement of these favors osteoarthritis or psoriatic arthritis. The cervical spine (C1–C2) is the one spinal level RA can attack, producing atlantoaxial instability — clinically relevant before any intubation or surgery.

Untreated RA cuts life expectancy by ~5–10 years primarily via accelerated atherosclerosis; RA is a cardiovascular risk equivalent, akin to diabetes, for prevention decisions.

Presentation Patterns and Key History

— MCPs, PIPs, wrists, MTPs > knees, elbows, shoulders, ankles, cervical spine.

— Symmetric involvement is the hallmark.

— DIPs, thoracolumbar spine, SI joints are spared.

— Duration of morning stiffness (>60 min suggests inflammatory).

— Improvement with activity vs worsening (inflammatory improves; mechanical worsens).

— Family history of RA, autoimmune disease, psoriasis, IBD.

— Smoking history — smoking is the strongest modifiable risk factor and amplifies anti-CCP production, especially in HLA-DR4 (shared epitope) carriers.

— Recent infections (parvovirus B19, hepatitis B/C, gonococcal), tick exposure (Lyme), psoriasis, low back pain (spondyloarthropathy), Raynaud or rash (SLE).

— Reproductive plans (impacts DMARD choice — methotrexate and leflunomide are teratogenic).

— Functional impact: grip strength, work disability, ADLs.

Classic insidious onset (~70%): weeks-to-months of progressive symmetric hand/wrist/foot pain and stiffness; patient often presents because they can no longer open jars or button shirts.

Palindromic onset: episodic mono- or oligoarthritis lasting hours to days with complete resolution between attacks; ~50% evolve into persistent RA, especially if anti-CCP positive.

Acute polyarticular onset (~10%): abrupt "flu-like" syndrome with fever, fatigue, and polyarthritis — mimics viral arthritis; persistence beyond 6 weeks shifts diagnosis toward RA.

Joint distribution clues:

Key history questions on Step 3 stems:

Extra-articular red flags suggesting established or severe RA: rheumatoid nodules, dry eyes/mouth (secondary Sjögren), pleuritic chest pain, dyspnea (ILD), foot drop (vasculitic neuropathy), scleritis.

Key distinction: Inflammatory vs mechanical arthritis — inflammatory features include morning stiffness >60 min, improvement with use, symmetric small-joint swelling, elevated CRP/ESR. Mechanical (OA) features include stiffness <30 min, worsening with use, DIP involvement (Heberden nodes), bony enlargement, normal inflammatory markers.

Board pearl: A middle-aged smoker with 2 months of symmetric MCP/wrist swelling and morning stiffness "until lunchtime" is RA until proven otherwise — order anti-CCP first.

Physical Exam Findings

— Synovitis = soft, warm, "boggy" swelling with tenderness on palpation; the cardinal exam finding.

— Squeeze test: transverse compression across MCPs or MTPs eliciting pain is a sensitive bedside screen.

— Reduced range of motion, especially wrist dorsiflexion and finger flexion.

— Symmetric distribution: confirm bilateral involvement.

— Ulnar deviation at MCPs.

— Swan-neck deformity: PIP hyperextension, DIP flexion.

— Boutonnière deformity: PIP flexion, DIP hyperextension.

— Z-thumb, MCP subluxation, piano-key sign at distal ulna.

— Rheumatoid nodules: firm, mobile, subcutaneous, over extensor surfaces (olecranon, MCPs); ~25% of seropositive RA.

— Lungs: bibasilar dry crackles (ILD), pleural rub.

— Eyes: dry eyes, episcleritis, scleritis (painful red eye → urgent ophthalmology).

— Skin: palmar erythema, vasculitic ulcers, leukocytoclastic purpura.

— Splenomegaly + neutropenia + RA = Felty syndrome.

— Carpal tunnel signs (Tinel, Phalen) from wrist synovitis.

General inspection: assess gait, ability to remove coat, shake hands (grip strength is a quick functional metric).

Joint exam — look, feel, move:

Hand deformities of established RA (late findings — should not occur with early treatment):

Foot: MTP tenderness on squeeze, hallux valgus, hammer toes, forefoot widening, "walking on marbles" sensation.

Cervical spine: test for atlantoaxial instability — neck pain radiating to occiput, paresthesias, Lhermitte sign; always evaluate before elective intubation.

Extra-articular exam:

Hemodynamic considerations: RA is not a hemodynamic disease per se, but pericardial effusion and rarely tamponade can occur — check for pulsus paradoxus, muffled heart sounds, JVD if dyspneic. Screen all RA patients for traditional CV risk factors at every visit.

Board pearl: Symmetric MCP/wrist synovitis + positive squeeze test + morning stiffness >1 hour = order anti-CCP and refer.

Step 3 management: Document a tender joint count (TJC) and swollen joint count (SJC) at baseline — required for DAS28/CDAI scoring and treat-to-target follow-up.

Diagnostic Workup — Initial Labs and Imaging

— Rheumatoid factor (RF): IgM against Fc of IgG; sensitivity ~70%, specificity ~80%. Also positive in hepatitis C, Sjögren, endocarditis, sarcoid, cryoglobulinemia, and ~5% of healthy elderly.

— Anti-CCP (ACPA): sensitivity ~70%, specificity ~95% — the single most useful diagnostic antibody. High titers predict erosive, more aggressive disease.

— Both positive → very high specificity; "double seropositive" = worse prognosis, earlier aggressive therapy.

— ESR and CRP — elevated in ~60%; track disease activity over time. Normal markers do not rule out RA (~40% have normal ESR/CRP at presentation).

— CBC with differential, comprehensive metabolic panel (LFTs, creatinine), albumin.

— Hepatitis B surface antigen, core antibody, hepatitis C antibody (reactivation risk with biologics, MTX).

— HIV screening.

— TB screening: interferon-gamma release assay (IGRA, preferred) or PPD — required before TNF inhibitors and other biologics; chest X-ray if positive.

— Pregnancy test in women of childbearing potential.

— Lipid panel and HbA1c (RA = CV risk equivalent).

— Plain radiographs of hands (PA) and feet (PA) bilaterally at baseline. Early findings: periarticular osteopenia, soft tissue swelling, marginal joint-space narrowing; erosions are a later finding but, when present at baseline, prompt urgent aggressive therapy.

— Films also screen for alternative diagnoses (chondrocalcinosis, OA, erosive psoriatic disease with "pencil-in-cup").

— Joint involvement (0–5), serology (RF/anti-CCP, 0–3), acute-phase reactants (0–1), symptom duration ≥6 weeks (0–1).

Serology (order both — they are complementary):

Inflammatory markers:

Baseline labs before DMARD initiation (mandatory):

Imaging — initial:

2010 ACR/EULAR classification criteria (score ≥6/10 classifies as definite RA):

Key distinction: Classification criteria are for research/trials — do not require all criteria to start treatment. A clinical diagnosis of inflammatory polyarthritis warrants DMARD initiation even with score <6 if clinical gestalt fits.

Board pearl: Order anti-CCP, RF, CRP, ESR, CBC, CMP, hepatitis B/C, TB IGRA, and hand/foot X-rays as a single initial bundle — this is the canonical "first visit" workup.

Diagnostic Workup — Advanced and Confirmatory Studies

— Detects subclinical synovitis and small erosions before radiographs change.

— Power Doppler signal indicates active inflammation and predicts erosive progression.

— Helps differentiate active synovitis from chronic fibrotic swelling — guides treatment escalation decisions.

— Most sensitive for early bone marrow edema (osteitis) — the strongest imaging predictor of future erosion.

— Indicated when diagnosis is uncertain, X-rays are normal, and exam is equivocal.

— Not routine for follow-up due to cost.

— Indicated when monoarthritis or acute flare — must exclude septic arthritis and crystal disease before escalating immunosuppression.

— Typical RA synovial fluid: inflammatory (WBC 2,000–50,000, neutrophil predominant), sterile, no crystals.

— Always send Gram stain, culture, crystals, cell count.

— ANA — positive in ~30% of RA; high titer or specific antibodies (anti-dsDNA, anti-Sm) shift toward SLE.

— Anti-Ro/La — Sjögren overlap.

— HLA-B27 — if axial/SI involvement suggests spondyloarthropathy.

— Parvovirus B19 IgM, hepatitis C RNA, Lyme serology — if acute polyarthritis with exposures.

— Baseline chest X-ray in all; high-resolution CT if dyspnea, dry cough, hypoxemia, or bibasilar crackles (RA-ILD, usually UIP pattern).

— PFTs with DLCO if HRCT abnormal or before pulmonary-toxic DMARDs (MTX, leflunomide).

MSK ultrasound (increasingly available in rheumatology clinics):

MRI of hands/wrists:

Joint aspiration (arthrocentesis):

Additional autoimmune serologies if atypical features:

Pulmonary evaluation:

Cervical spine imaging: flexion/extension cervical X-rays in long-standing RA or before any elective surgery requiring intubation — assess for atlantoaxial subluxation (anterior atlanto-dental interval >3 mm).

DXA scan: baseline in patients starting chronic glucocorticoids (≥5 mg prednisone daily for ≥3 months).

Step 3 management: A patient with new symmetric polyarthritis but negative RF and anti-CCP still warrants rheumatology referral — seronegative RA is ~30% of cases and can be just as erosive; ultrasound or MRI confirms synovitis.

Board pearl: Acute monoarticular flare in an established RA patient → tap the joint first, do not assume RA flare; septic arthritis incidence is elevated in RA.

Risk Stratification and Treat-to-Target Logic

— Define a target: clinical remission (preferred, especially in early disease) or low disease activity (acceptable in long-standing disease).

— Measure disease activity at every visit using a validated composite: DAS28-CRP, CDAI, SDAI, or RAPID3.

— Re-evaluate every 1–3 months in active disease; escalate therapy if target not met by 3 months and definitely by 6 months.

— Step down (don't stop) only after sustained remission ≥6 months.

— Remission <2.6; low 2.6–3.2; moderate >3.2–5.1; high >5.1.

— High anti-CCP or RF titers.

— Erosions on baseline imaging.

— High joint count, elevated CRP/ESR.

— Functional limitation (HAQ score).

— Extra-articular manifestations (nodules, ILD, vasculitis).

— Failure of initial conventional DMARD.

— All patients with active RA should start a DMARD as soon as diagnosed — ideally within the 12-week window.

— Methotrexate (MTX) monotherapy is first-line for nearly all patients regardless of severity.

— Short-course bridging glucocorticoids (low-dose prednisone, e.g., 5–10 mg/day, tapered over weeks) may be used while DMARD takes effect — avoid chronic steroids.

— NSAIDs are symptomatic only — they do not modify disease.

Treat-to-target (T2T) is the central paradigm of modern RA care:

Disease activity categories (DAS28-CRP):

Poor prognostic factors that mandate more aggressive initial therapy:

Initial management logic (2021 ACR guideline):

If MTX inadequate at 3 months: add a biologic DMARD (preferred TNF inhibitor) or JAK inhibitor, or switch within conventional DMARD class (triple therapy: MTX + sulfasalazine + hydroxychloroquine).

CCS pearl: On a CCS-style case, the moment a patient meets RA criteria, order methotrexate, folic acid 1 mg daily, baseline labs, hepatitis/TB screen, and schedule rheumatology follow-up in 4–6 weeks. Do not delay DMARD waiting for "more data."

Board pearl: The strongest predictor of long-term joint preservation is how soon after symptom onset the first DMARD is started — every month of delay matters.

Pharmacotherapy — First-Line DMARD Regimen

— Mechanism: dihydrofolate reductase inhibition + adenosine-mediated anti-inflammatory effects.

— Dose: start 10–15 mg PO once weekly, titrate to 20–25 mg weekly over 4–8 weeks. Subcutaneous if oral inadequate response, GI intolerance, or dose >15 mg (better bioavailability).

— Always co-prescribe folic acid 1 mg daily (or 5 mg weekly) — reduces stomatitis, GI side effects, hepatotoxicity, cytopenias without loss of efficacy.

— Onset: 6–12 weeks.

— Pregnancy (Category X — teratogenic, abortifacient), breastfeeding.

— CrCl <30 mL/min, significant liver disease, heavy alcohol use, untreated hepatitis B/C, active infection, blood dyscrasias.

— Pulmonary fibrosis (relative — MTX pneumonitis risk).

— CBC, ALT/AST, creatinine, albumin every 2–4 weeks for first 3 months, then every 8–12 weeks.

— Hold for ALT >3× ULN, significant cytopenia, new dyspnea/cough (pneumonitis), oral ulcers.

— Hydroxychloroquine (mild disease): retinal toxicity monitoring — baseline + annual ophthalmology after 5 years.

— Sulfasalazine: check G6PD if at risk; monitor CBC, LFTs.

— Leflunomide: teratogenic (washout with cholestyramine before pregnancy); hepatotoxicity, HTN.

— Low-dose prednisone (≤10 mg/day) as bridge for 2–3 months, then taper off as DMARD takes effect.

— Intra-articular steroid injection for isolated joint flares.

— Avoid chronic steroids — osteoporosis, diabetes, infection, CV risk. If unavoidable, add calcium 1000–1200 mg, vitamin D 800 IU, and bisphosphonate if dose ≥5 mg/day ≥3 months and elevated fracture risk.

— Update influenza (annual), pneumococcal (PCV20 or PCV15+PPSV23), zoster (recombinant), COVID-19, HBV before biologics if possible.

— No live vaccines (MMR, varicella, yellow fever, intranasal flu) once on biologics or high-dose immunosuppression.

Methotrexate (MTX) — anchor drug:

MTX contraindications/cautions:

MTX monitoring:

Alternative first-line if MTX contraindicated:

Adjunctive glucocorticoids:

Vaccinations before/during DMARD therapy:

Board pearl: MTX + folic acid + bridging prednisone is the prototypical Step 3 answer for newly diagnosed RA.

Expanded Pharmacology — Biologics, JAK Inhibitors, and Combinations

— Etanercept (soluble receptor, SC weekly), adalimumab (SC q2 weeks), infliximab (IV q8 weeks), golimumab, certolizumab.

— Combine with MTX when possible — reduces anti-drug antibody formation and improves efficacy.

— Screen for latent TB (IGRA), hepatitis B/C, HIV before initiation; treat latent TB before starting.

— Risks: serious infections (esp. intracellular — TB, histoplasmosis, listeria), demyelinating disease (avoid in MS), worsens NYHA III–IV heart failure, drug-induced lupus.

— Abatacept (CTLA-4 Ig, T-cell co-stim blocker) — favorable safety in ILD.

— Rituximab (anti-CD20) — preferred in RA with lymphoma history, demyelinating disease, or ILD.

— Tocilizumab, sarilumab (IL-6 receptor blockers) — monitor LFTs, lipids, neutrophils; risk of GI perforation (caution with diverticulitis history).

— Tofacitinib, baricitinib, upadacitinib.

— Boxed warning (ORAL Surveillance trial): increased MACE, malignancy, VTE, and mortality vs TNF inhibitors in patients ≥50 with ≥1 CV risk factor.

— 2021 ACR update: prefer TNF inhibitors over JAK inhibitors; reserve JAKs for patients who fail or cannot tolerate biologics, or who prefer oral therapy after risk discussion.

— After ≥6 months of sustained remission, consider tapering (spacing doses, reducing dose) — do not abruptly stop. MTX is typically the last drug withdrawn.

When to escalate beyond MTX: moderate–high disease activity persisting at 3 months despite optimized MTX dose, or poor prognostic features at baseline.

TNF-α inhibitors (first-line biologic class):

Non-TNF biologics (after TNF failure or specific contraindications):

JAK inhibitors (oral):

Triple oral therapy: MTX + sulfasalazine + hydroxychloroquine — non-inferior to MTX + TNFi in some trials; useful when biologics unaffordable or contraindicated.

Therapy de-escalation:

Key distinction: Biologics ≠ DMARDs are not interchangeable — always screen for TB, hepatitis B/C, HIV before any biologic or JAK inhibitor; update vaccines first.

Step 3 management: A patient on MTX + adalimumab who develops fever and cough → hold biologic, broaden infection workup including TB and opportunistic pathogens, chest imaging, blood cultures; do not assume simple URI.

Special Populations — Elderly and Renal/Hepatic Impairment

— More acute onset, more constitutional symptoms, higher ESR, more shoulder/large-joint involvement — may mimic polymyalgia rheumatica (PMR).

— Key distinction: PMR features bilateral shoulder/hip girdle pain/stiffness, very high ESR, dramatic response to low-dose prednisone (15 mg), and no synovitis on exam or imaging. RA features peripheral synovitis and seropositivity.

— Treatment principles unchanged, but increased risk of MTX toxicity, infection, comorbidities — start low, go slow; monitor more frequently.

— MTX is renally cleared — contraindicated if CrCl <30, dose-reduce and monitor closely 30–60. Accumulation → cytopenias, mucositis, hepatotoxicity.

— Leflunomide: caution, no firm cutoff; monitor.

— Hydroxychloroquine, sulfasalazine: generally safe; sulfasalazine accumulates in severe CKD.

— TNF inhibitors, abatacept, rituximab, tocilizumab: no significant renal dose adjustment needed — preferred in CKD.

— JAK inhibitors: dose-adjust (e.g., tofacitinib 5 mg daily in moderate–severe renal impairment).

— Avoid NSAIDs in CKD stage ≥3.

— MTX and leflunomide are hepatotoxic — contraindicated in chronic liver disease, active hepatitis, heavy alcohol use (>1 drink/day is a relative contraindication for MTX).

— Screen all patients for hepatitis B/C before MTX or biologics; treat active HCV; provide HBV prophylaxis with entecavir/tenofovir if HBsAg+ or anti-HBc+ starting rituximab or other potent immunosuppression.

— Hydroxychloroquine and most biologics are safer hepatically.

— MTX + trimethoprim-sulfamethoxazole → severe pancytopenia (additive antifolate effect) — avoid.

— MTX + NSAIDs at high doses → reduced renal clearance, toxicity (low-dose RA MTX usually tolerable with NSAIDs but monitor).

— Live zoster vaccine contraindicated on biologics — use recombinant zoster (Shingrix).

Elderly-onset RA (EORA, onset ≥60):

Renal impairment:

Hepatic impairment:

Polypharmacy and DDIs:

Board pearl: An elderly RA patient on MTX develops a UTI; the resident prescribes TMP-SMX → recognize the MTX–TMP-SMX antifolate interaction and choose an alternative antibiotic (nitrofurantoin, cephalexin per culture).

Step 3 management: Reassess GFR and LFTs every 8–12 weeks in elderly on MTX; reduce dose proactively as GFR declines.

Special Populations — Pregnancy, Lactation, and Reproductive Planning

— Stop methotrexate ≥1–3 months before conception in both women and men (teratogenic — neural tube defects, craniofacial, limb anomalies; abortifacient).

— Stop leflunomide and perform cholestyramine washout (8 g TID × 11 days) until two serum levels <0.02 mg/L; otherwise washout takes up to 2 years.

— Switch to pregnancy-compatible DMARDs before conception: hydroxychloroquine, sulfasalazine, azathioprine, certolizumab are considered safe.

— Certolizumab pegol — pegylated Fab fragment, minimal placental transfer, can be continued throughout pregnancy.

— Other TNF inhibitors (adalimumab, etanercept, infliximab) — generally continued through 2nd trimester, often through 3rd; if continued late, avoid live vaccines (rotavirus, BCG) in infant for 6–12 months.

— Avoid in pregnancy: MTX, leflunomide, mycophenolate, cyclophosphamide, tofacitinib/JAK inhibitors, rituximab (case-by-case).

— ~50–60% of RA patients experience improvement during pregnancy, but ~90% flare postpartum within 3 months — plan postpartum DMARD reintroduction.

— Compatible: hydroxychloroquine, sulfasalazine (caution in G6PD-deficient or premature infants), certolizumab, other TNF inhibitors (minimal milk transfer).

— Not compatible: MTX, leflunomide, JAK inhibitors, cyclophosphamide.

Preconception counseling is essential — Step 3 favors proactive planning:

Pregnancy-compatible biologic of choice:

Disease behavior in pregnancy:

Lactation:

Contraception: all women of childbearing age on MTX/leflunomide/JAK inhibitors require reliable contraception; counsel at every visit and document.

Pediatric considerations (JIA, not classic adult RA): brief mention — juvenile idiopathic arthritis treated by pediatric rheumatology with MTX, TNFi, IL-1/IL-6 blockade; uveitis screening is mandatory.

Fertility: RA itself may modestly reduce fertility; NSAIDs can impair ovulation and should be stopped when actively trying to conceive.

Board pearl: Hydroxychloroquine and certolizumab are the canonical "safe in pregnancy" RA drugs. MTX is the canonical teratogen to stop ≥3 months before conception with folic acid supplementation continued.

Step 3 management: A 30-year-old on MTX planning pregnancy → stop MTX now, continue folic acid, switch to hydroxychloroquine ± sulfasalazine, ± certolizumab if needed, and recheck disease activity in 4–8 weeks.

Complications and Adverse Outcomes

— Erosive joint destruction → deformities (ulnar deviation, swan-neck, boutonnière), subluxation, ankylosis, functional disability.

— Atlantoaxial subluxation (C1–C2) → cervical myelopathy; risk during neck manipulation/intubation.

— Tendon rupture (extensor tendons at wrist), carpal tunnel syndrome, Baker cyst rupture mimicking DVT.

— RA doubles MI and stroke risk; managed as a CV risk equivalent.

— Pericarditis, pericardial effusion (often silent), accelerated atherosclerosis.

— Tight inflammation control reduces CV events — another reason to treat to target.

— Interstitial lung disease (RA-ILD), usually UIP pattern — leading non-articular cause of mortality.

— Pleural effusion (exudative, very low glucose <30, low pH).

— Bronchiectasis, organizing pneumonia, MTX pneumonitis (acute hypersensitivity, eosinophilia on BAL).

— Caplan syndrome: RA + pneumoconiosis + lung nodules.

— Felty syndrome: RA + splenomegaly + neutropenia → recurrent infections.

— Large granular lymphocyte (LGL) leukemia association.

— Increased lymphoma risk (especially DLBCL) — driven by disease activity itself, not primarily by therapy.

— MTX: hepatotoxicity, cytopenias, pneumonitis, oral ulcers.

— Biologics: infection, malignancy (modest), infusion/injection reactions, demyelination (TNFi), heart failure exacerbation (TNFi).

Articular complications:

Cardiovascular:

Pulmonary:

Hematologic:

Ocular: keratoconjunctivitis sicca (secondary Sjögren), scleritis (painful, vision-threatening — urgent ophthalmology), episcleritis, peripheral ulcerative keratitis.

Vascular: rheumatoid vasculitis (small/medium vessel) — digital ischemia, mononeuritis multiplex, cutaneous ulcers, leukocytoclastic purpura.

Bone: osteoporosis (disease + glucocorticoids) — DXA, calcium/vitamin D, consider bisphosphonates per FRAX.

Amyloidosis (AA): rare in well-treated RA; presents with proteinuria, nephrotic syndrome.

Infection: increased risk from disease and immunosuppression — bacterial pneumonia, septic arthritis, herpes zoster (notably with JAK inhibitors), opportunistic infections.

Treatment-related:

Board pearl: New dyspnea in RA → think RA-ILD, MTX pneumonitis, opportunistic infection, pleural effusion, and PE — don't just write off cough.

Key distinction: Septic arthritis vs RA flare — always aspirate an acutely hot single joint, especially if febrile.

When to Escalate Care — Consults and Inpatient Triage

— New symmetric polyarthritis with morning stiffness >6 weeks.

— Positive anti-CCP or RF with clinical synovitis.

— Erosions on initial radiographs.

— Suspected systemic vasculitis (mononeuritis, ischemic digits, purpura).

— Severe functional limitation or refractory pain.

— Septic arthritis suspicion (acute mono-articular flare, fever, leukocytosis, very high CRP) — admit for IV antibiotics after joint tap, ortho consult for washout.

— Acute cervical myelopathy from atlantoaxial subluxation — emergent neurosurgery, MRI cervical spine, immobilize.

— Severe rheumatoid vasculitis (digital gangrene, mesenteric ischemia, foot drop) — inpatient high-dose steroids ± cyclophosphamide/rituximab.

— Acute RA-ILD exacerbation or MTX pneumonitis — admit, hold MTX, steroids, supportive O₂, exclude infection (often need bronchoscopy/BAL).

— Scleritis — same-day ophthalmology; risk of globe perforation.

— Serious infection on biologic (sepsis, opportunistic pathogen, TB reactivation).

— Pericardial tamponade — emergent echo and pericardiocentesis.

— Pulmonology for ILD, recurrent pulmonary infections.

— Ophthalmology for scleritis, hydroxychloroquine retinopathy screening.

— Cardiology for CV risk optimization.

— Orthopedic surgery for joint replacement (typically THA, TKA in burned-out disease) — coordinate perioperative DMARD management (continue MTX, hold biologics 1 dosing cycle before surgery, resume after wound healing per ACR/AAHKS guideline).

— Pain medicine / physiatry / OT/PT for functional rehab.

— Cervical spine flexion-extension films before intubation in long-standing RA.

— Hold biologics ~1 dosing interval before surgery; resume 14 days postop if wound healing well.

— Continue MTX, hydroxychloroquine, sulfasalazine through surgery.

— Stress-dose steroids only if chronic prednisone >5 mg/day and major surgery.

Urgent rheumatology referral (within days–weeks, not months):

Emergency department / inpatient indications:

Specialist co-management:

Perioperative checklist (Step 3 favorite):

CCS pearl: Septic joint in a known RA patient → joint aspiration STAT, blood cultures, empiric vancomycin + ceftriaxone, ortho consult, hold immunosuppression — these orders go in the first 30 minutes.

Step 3 management: Don't anchor on "RA flare" when fever or single-joint involvement is present — sepsis must be excluded.

Key Differentials — Other Inflammatory Arthropathies

— Asymmetric oligoarthritis, DIP involvement, dactylitis ("sausage digit"), enthesitis, nail pitting/onycholysis, psoriasis (may follow arthritis onset).

— RF, anti-CCP usually negative.

— X-ray: "pencil-in-cup" deformity, periostitis, asymmetric erosions.

— Inflammatory back pain in young men, sacroiliitis, improvement with exercise, HLA-B27 positive.

— Peripheral arthritis when present is asymmetric and lower-limb predominant.

— Asymmetric lower-limb oligoarthritis 1–4 weeks after GI (Salmonella, Shigella, Campylobacter, Yersinia) or GU (Chlamydia) infection.

— Conjunctivitis, urethritis, keratoderma blennorrhagicum; HLA-B27 association.

— Gout: acute monoarticular, podagra, MSU crystals (negatively birefringent, needle-shaped); can become polyarticular and mimic RA ("gouty RA"). Synovial fluid analysis is diagnostic.

— CPPD/pseudogout: chondrocalcinosis on X-ray, rhomboid positively birefringent crystals; can present as RA-like polyarthritis in elderly.

— Age ≥50, bilateral shoulder/hip girdle pain and stiffness, ESR markedly elevated, no synovitis, dramatic response to prednisone 15 mg/day. Associated with giant cell arteritis — screen for headache, jaw claudication, vision changes.

— Quotidian fevers, evanescent salmon-pink rash, arthritis, sore throat, very high ferritin (>1000), leukocytosis; RF and ANA negative.

— Monoarticular acute swelling + fever — emergency. Bacterial (Staph aureus most common), gonococcal (young sexually active, tenosynovitis + pustular skin lesions + polyarthralgia triad), Lyme, viral.

— DIP involvement: PsA, OA, not RA.

— Asymmetric, lower-limb, enthesitis: spondyloarthropathy, not RA.

— Acute monoarthritis with fever: septic or crystal, not RA flare.

Psoriatic arthritis (PsA):

Ankylosing spondylitis / axial spondyloarthritis:

Reactive arthritis:

Crystal arthropathies:

Polymyalgia rheumatica (PMR):

Adult-onset Still disease:

Septic / infectious arthritis:

Key distinction grid:

Board pearl: A patient with "RA" that doesn't respond to MTX and has nail pitting → reconsider psoriatic arthritis; serology often negative and treatment overlaps (MTX, TNFi, IL-17/IL-23 blockers).

Key Differentials — Non-Rheumatic and Other-Category Mimics

— Most common mimic in primary care.

— DIPs (Heberden), PIPs (Bouchard), first CMC, knees, hips, lumbar/cervical spine.

— Morning stiffness <30 minutes, worsens with activity, bony hypertrophy (not boggy synovitis).

— Normal CRP/ESR; X-ray shows joint-space narrowing, osteophytes, subchondral sclerosis/cysts; no erosions.

— Non-erosive, deforming arthritis (Jaccoud arthropathy), plus malar rash, photosensitivity, serositis, cytopenias, nephritis, neurologic involvement.

— Anti-dsDNA, anti-Sm specific; ANA highly sensitive. Significant overlap exists ("rhupus" = RA + SLE).

— Sicca symptoms, anti-Ro/La, parotid enlargement; arthritis is mild and non-erosive (when primary).

— Parvovirus B19: acute symmetric small-joint polyarthritis in adults exposed to children with "slapped cheek"; usually resolves in weeks; RF may be transiently positive.

— Hepatitis B/C, HIV, chikungunya, rubella, EBV. Hep C with cryoglobulinemia can cause RF-positive arthritis, mimicking RA — always check hepatitis C in a new RF-positive arthritis.

Osteoarthritis (OA):

Systemic lupus erythematosus (SLE):

Sjögren syndrome:

Viral arthritis:

Endocarditis: can present with arthritis, RF positive, low complements — examine for murmur, get blood cultures and echo before labeling RA.

Hemochromatosis: 2nd and 3rd MCP arthropathy with "hook" osteophytes on X-ray, chondrocalcinosis, hyperpigmentation, diabetes, cirrhosis — check ferritin and transferrin saturation in any "atypical RA."

Thyroid disease: hypothyroidism causes arthralgias, carpal tunnel, myalgia — check TSH.

Fibromyalgia: widespread pain, tender points, no synovitis, normal labs/imaging; often coexists with RA and complicates disease-activity assessment.

Sarcoidosis: Löfgren syndrome (bilateral hilar adenopathy + erythema nodosum + ankle arthritis) is acute and self-limited; chronic sarcoid arthropathy is rare.

Paraneoplastic / hematologic: new symmetric polyarthritis in older adults, weight loss, atypical features → consider underlying malignancy or remitting seronegative symmetric synovitis with pitting edema (RS3PE).

Board pearl: Check hepatitis C and ferritin in every new RF-positive arthritis — both are common mimics and modify therapy.

Key distinction: OA stiffness is brief and worsens with use; RA stiffness is prolonged and improves with use — single best history question to triage.

Secondary Prevention, Long-Term Plan, and Discharge Considerations

— Continue scheduled DMARD/biologic with composite disease activity scoring at each visit.

— Once sustained remission ≥6 months: consider stepping down (extending biologic dosing intervals, lowering MTX) — never abruptly stop; ~50% flare with full withdrawal.

— Annual lipid panel, BP, diabetes screening.

— Statin per ASCVD risk; threshold to treat is lower than for non-RA patients (multiply 10-year ASCVD risk by ~1.5 per EULAR).

— Smoking cessation — also reduces RA disease activity and improves DMARD response.

— Mediterranean diet, regular aerobic + resistance exercise.

— Calcium 1000–1200 mg/day + vitamin D 800–1000 IU/day.

— DXA baseline if chronic steroids; bisphosphonate if prednisone ≥5 mg/day for ≥3 months and elevated fracture risk (FRAX).

— Influenza (inactivated) annually.

— Pneumococcal: PCV20 alone or PCV15 followed by PPSV23.

— Recombinant zoster (Shingrix) age ≥19 if immunosuppressed; ≥50 routine.

— HBV series if at risk and seronegative.

— COVID-19 per current schedule.

— No live vaccines on biologics/JAK inhibitors/high-dose steroids (>20 mg prednisone).

— Joint protection, energy conservation, hand splints, assistive devices via OT.

— Aquatic exercise, low-impact aerobic activity.

— Disease self-monitoring with RAPID3 or symptom diary.

Treat-to-target maintenance:

Cardiovascular risk reduction (RA = CV risk equivalent):

Bone health:

Vaccinations (annual review):

Cancer screening: maintain standard age-appropriate screening (mammography, colonoscopy, cervical, lung CT if eligible); add skin exams annually on TNF inhibitors and JAK inhibitors.

Mental health: screen for depression and anxiety (PHQ-9, GAD-7) — high prevalence; treat aggressively as it impacts disease perception and adherence.

Patient self-management:

Medication adherence: discuss cost, insurance/specialty pharmacy logistics; biologic copay assistance programs.

Step 3 management: At every RA follow-up, run a structured checklist — disease activity score, MTX/biologic labs due?, vaccine status, lipid/BP/A1c, mood screen, bone health, contraception/pregnancy planning.

Board pearl: A 55-year-old RA patient with LDL 130 and 10-year ASCVD risk of 7% → consider statin therapy — RA upgrades CV risk and lowers treatment threshold.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Active disease: every 1–3 months with disease activity scoring; escalate at 3 months if target not met.

— Stable, in remission/low disease activity: every 6–12 months.

— Primary care concurrent visits for CV, bone, vaccine, mental health.

— MTX, leflunomide, sulfasalazine, azathioprine: CBC, ALT/AST, creatinine, albumin every 2–4 weeks for first 3 months, then every 8–12 weeks.

— Hydroxychloroquine: no routine labs; baseline + annual ophthalmology after 5 years (or earlier if renal disease, tamoxifen use, or dose >5 mg/kg actual body weight).

— Biologics: CBC, LFTs every 3–6 months; annual TB screening (IGRA) on TNF inhibitors per local prevalence.

— Tocilizumab/sarilumab: LFTs, lipids, neutrophils every 4–8 weeks initially; CRP becomes unreliable on IL-6 blockade.

— JAK inhibitors: lipids 4–8 weeks after start; CBC, LFTs periodically.

— Hand/foot radiographs at 6–12 months to assess radiographic progression in active disease.

— Repeat MRI or US guides treatment intensification in selected cases.

— Refer to occupational therapy for hand splinting, adaptive equipment, joint protection education.

— Physical therapy for range of motion, low-impact aerobic, strengthening, posture.

— Encourage regular exercise — improves disease activity, fatigue, CV risk, mood.

— Smoking cessation counseling at every visit (5 A's).

— Weight management — obesity reduces DMARD response and worsens cardiometabolic risk.

— Discuss expected 6–12 week onset of MTX to avoid premature discontinuation.

— Folic acid daily — confirm patient understands the difference from once-weekly MTX (medication errors with daily MTX dosing have caused fatal pancytopenia).

Visit cadence:

Lab monitoring schedule (key Step 3 detail):

Imaging follow-up:

Functional and rehab counseling:

Adherence counseling:

Sick day rules: hold MTX and biologics during serious infections; resume after recovery. Avoid live vaccines. Use antipyretics, hydrate.

Board pearl: The single most dangerous RA medication error is daily methotrexate instead of weekly → fatal cytopenias. Every prescription should state "once weekly" boldly and patient education must verify.

Step 3 management: Provide a written medication and monitoring plan at each visit — a Step 3 favorite for patient safety scoring.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of infection risk (including TB reactivation), malignancy risk, infusion reactions, cost, vaccination requirements, and pregnancy implications.

— JAK inhibitors require explicit discussion of the boxed warning (MACE, VTE, malignancy, mortality vs TNFi), particularly in patients ≥50 with CV risk factors — and documented shared decision-making.

— MTX and leflunomide are teratogenic in both sexes (men should also discontinue MTX before attempting conception per most guidelines, though data weaker).

— Document contraception counseling at each visit in patients of reproductive potential — a frequent litigation source.

— Adolescent confidentiality: when prescribing teratogens to minors, navigate state-specific rules around contraceptive counseling without parental disclosure.

— Weekly MTX dosing errors (taken daily) → fatal pancytopenia. Use blister packs, day-of-week prescriptions ("methotrexate weekly, on Sundays"), pharmacy alerts, and confirmed patient teach-back.

— Avoid the MTX–TMP-SMX interaction; flag in EHR.

— Reconcile DMARDs at every transition of care.

— Hospital admission: ensure rheumatology is notified; hold biologic during active infection, continue MTX unless contraindicated, stress-dose steroids if chronically on prednisone ≥5 mg.

— Discharge: explicit plan for resuming biologic and outpatient rheum follow-up within 2–4 weeks; mark labs due, vaccines due.

— Newly diagnosed active TB during pre-biologic screening → report to public health.

— Suspected elder abuse if functional decline + suspicious findings — many RA patients depend on caregivers.

— Biologics often require prior authorization; document failure/intolerance of conventional DMARDs to justify.

— Discuss biosimilars (substitution may occur at pharmacy level) and copay assistance.

Informed consent for biologics/JAK inhibitors:

Pregnancy and teratogen counseling:

Medication safety:

Transitions of care:

Mandatory reporting and public health:

Health systems/access:

Capacity and adherence: chronic disease with cognitive or functional decline → assess medication self-management capacity; involve caregivers or pill organizers.

Board pearl: A patient on infliximab develops productive cough and fever 2 months after starting → rule out TB reactivation even if pre-treatment IGRA was negative; report confirmed cases.

Step 3 management: At every biologic initiation, document a structured safety checklist: TB, hepatitis B/C, HIV, vaccines, pregnancy plan, infection precautions, and emergency contact plan.

High-Yield Associations and Rapid-Fire Clinical Facts

Genetic: HLA-DR4 and HLA-DR1 shared epitope → increased susceptibility and severity, especially with smoking.

Smoking is the strongest modifiable risk factor — promotes citrullination, raises anti-CCP, reduces DMARD/biologic response.

Anti-CCP is more specific than RF and predicts erosive disease.

Felty syndrome: RA + splenomegaly + neutropenia. Mnemonic: "FAR" — Felty = Anemia/neutropenia + RA + splenomegaly.

Caplan syndrome: RA + pneumoconiosis + pulmonary nodules.

Sjögren can be primary or secondary to RA (sicca symptoms in RA = secondary Sjögren).

RA pleural effusion: exudate with very low glucose (<30), low pH, low complement — near-diagnostic combination.

Most common cause of mortality: cardiovascular disease; second most common pulmonary (ILD).

Lymphoma risk is increased ~2–3× in active RA — driven by disease activity, not therapy.

Cervical spine: atlantoaxial subluxation; obtain flexion/extension films before elective intubation.

Methotrexate = anchor; weekly dosing + daily folic acid.

TNF inhibitors: screen TB, hepatitis B/C, HIV before starting. Avoid in NYHA III–IV HF and demyelinating disease.

Rituximab preferred in RA with lymphoma history, ILD, or demyelinating disease.

JAK inhibitor boxed warning: MACE, VTE, malignancy, mortality.

Pregnancy-safe: hydroxychloroquine, sulfasalazine, azathioprine, certolizumab.

Hydroxychloroquine retinopathy screening: baseline + annual ophthalmology after 5 years (or sooner with renal disease or dose >5 mg/kg).

RS3PE: elderly, symmetric, pitting edema of dorsum of hands, dramatic steroid response, RF/anti-CCP negative — paraneoplastic workup.

MTX + TMP-SMX = pancytopenia.

Live vaccines contraindicated on biologics — use recombinant zoster (Shingrix).

Adult-onset Still: quotidian fever, salmon rash, very high ferritin.

Board pearl: A 45-year-old smoker with anti-CCP+, RF+, MCP synovitis, erosions on X-ray = aggressive seropositive RA — start MTX + early biologic strongly considered, do not delay.

Key distinction: Erosions = irreversible; the goal of early DMARD initiation is to prevent erosions from ever appearing.

Board Question Stem Patterns

— 42-year-old woman, smoker, 8 weeks of symmetric MCP/wrist swelling and 90 minutes morning stiffness. Anti-CCP positive, RF positive, CRP elevated. Best next step? → Start methotrexate with folic acid, refer to rheumatology, baseline labs and TB/hepatitis screen, hand/foot X-rays. Do not start NSAIDs alone, do not wait for rheumatology, do not start chronic high-dose prednisone.

— 30-year-old RA patient on MTX wants to conceive. Best next step? → Stop methotrexate now, switch to hydroxychloroquine ± sulfasalazine, ± certolizumab; continue folic acid; advise contraception for ≥1–3 months before attempting conception.

— Known RA patient on MTX + adalimumab presents with fever and acutely swollen knee. Best next step? → Arthrocentesis (Gram stain, culture, crystals, cell count), blood cultures, empiric IV antibiotics; do not assume RA flare.

— RA patient with inadequate MTX response, about to start a TNF inhibitor. Best next step? → TB screening (IGRA), hepatitis B and C, HIV, update vaccines, then initiate.

— RA patient on MTX develops UTI; resident plans TMP-SMX. Best next step? → Choose a different antibiotic (e.g., nitrofurantoin) — additive antifolate effect causes pancytopenia.

— RF-positive arthritis with cryoglobulinemia and elevated transaminases. Best next step? → Test for hepatitis C — it's a mimic, not RA.

— RA patient on MTX + abatacept scheduled for total knee arthroplasty. Management? → Continue MTX, hold abatacept one dosing interval before surgery and resume 14 days postop with wound healing. Cervical spine flexion-extension X-rays before intubation in long-standing RA.

— Patient on HCQ for 5 years. Next step? → Refer for ophthalmology screening (baseline done; annual after 5 years).

— RA patient on MTX develops subacute dry cough, dyspnea, hypoxemia. Next step? → Hold MTX, obtain HRCT, exclude infection, consider MTX pneumonitis vs RA-ILD; corticosteroids if pneumonitis confirmed.

Stem 1 — The classic early-RA diagnosis:

Stem 2 — Pregnancy planning:

Stem 3 — Acute monoarthritis in established RA:

Stem 4 — Pre-biologic screening:

Stem 5 — MTX safety interaction:

Stem 6 — Atypical "RA":

Stem 7 — Perioperative:

Stem 8 — Hydroxychloroquine monitoring:

Stem 9 — Pulmonary complication on MTX:

Step 3 management: Each stem rewards decisive, guideline-anchored action, screening prior to immunosuppression, and not anchoring on flare when sepsis is possible.

One-Line Recap

Early, persistent symmetric small-joint inflammatory arthritis should be diagnosed within weeks using anti-CCP, RF, CRP/ESR, and radiographs, then treated immediately with methotrexate plus folic acid (escalating to a TNF inhibitor or other biologic if target not met by 3 months) under a treat-to-target strategy aimed at clinical remission, with proactive screening, vaccination, cardiovascular risk reduction, and pregnancy planning embedded throughout care.

Diagnose fast, treat faster: The 12-week "window of opportunity" after symptom onset is when DMARD initiation produces the largest, most durable prevention of erosive joint damage and disability — every month of delay is irreversible.

Methotrexate is the anchor: Start 10–15 mg PO weekly (titrate to 20–25 mg, SC if needed) with daily folic acid; bridge with low-dose prednisone short-course; never daily MTX (fatal pancytopenia).

Screen before you suppress: Before any biologic or JAK inhibitor — TB (IGRA), hepatitis B/C, HIV, vaccinations updated (no live vaccines on biologics), pregnancy plan, baseline CBC/LFTs/Cr.

Treat-to-target & comorbidities: Reassess disease activity (DAS28/CDAI) every 1–3 months; escalate if not at target by 3–6 months. Manage RA as a cardiovascular risk equivalent, screen for osteoporosis, monitor mood, and counsel on smoking cessation — the single most powerful modifiable factor for both disease activity and prognosis.

Board pearl: When in doubt on a Step 3 stem about new symmetric polyarthritis with positive anti-CCP — start methotrexate, refer to rheumatology, complete pre-immunosuppression screening, and follow up in 4–6 weeks. That sequence wins almost every question.